GeoWealth Management LLC boosted its stake in Sanofi (NASDAQ:SNY - Free Report) by 56.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,256 shares of the company's stock after purchasing an additional 5,500 shares during the period. GeoWealth Management LLC's holdings in Sanofi were worth $736,000 at the end of the most recent reporting period.
Other hedge funds also recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new position in Sanofi during the 4th quarter worth approximately $135,933,000. Boston Partners grew its position in Sanofi by 86.4% in the 4th quarter. Boston Partners now owns 5,396,531 shares of the company's stock valued at $260,607,000 after buying an additional 2,501,073 shares in the last quarter. Magnetar Financial LLC increased its stake in shares of Sanofi by 104.3% during the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company's stock valued at $161,103,000 after acquiring an additional 1,705,148 shares during the period. DAVENPORT & Co LLC raised its stake in shares of Sanofi by 40.7% in the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company's stock worth $110,715,000 after buying an additional 664,455 shares in the last quarter. Finally, Thrivent Financial for Lutherans boosted its position in shares of Sanofi by 36.0% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,943,761 shares of the company's stock valued at $93,774,000 after purchasing an additional 514,542 shares in the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.
Sanofi Stock Down 2.3 %
Shares of NASDAQ:SNY traded down $1.22 on Friday, reaching $52.32. The company had a trading volume of 5,488,689 shares, compared to its average volume of 2,372,473. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $132.17 billion, a P/E ratio of 21.01, a P/E/G ratio of 1.01 and a beta of 0.57. The stock has a 50-day moving average price of $54.53 and a 200 day moving average price of $52.09. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12.
Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The company had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. On average, equities analysts expect that Sanofi will post 4.36 EPS for the current year.
Sanofi Increases Dividend
The firm also recently declared an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be given a $2.0369 dividend. This is an increase from Sanofi's previous annual dividend of $1.48. This represents a yield of 3.1%. The ex-dividend date is Friday, May 9th. Sanofi's payout ratio is currently 57.14%.
Analyst Ratings Changes
SNY has been the topic of several recent analyst reports. The Goldman Sachs Group assumed coverage on Sanofi in a report on Friday, March 21st. They set a "neutral" rating and a $65.00 price objective on the stock. BNP Paribas initiated coverage on Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 target price for the company. Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Finally, Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Sanofi currently has a consensus rating of "Moderate Buy" and a consensus target price of $63.33.
Read Our Latest Report on SNY
About Sanofi
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Further Reading
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
